New hope for patients with severe Muscle-Weakening disease that other treatments failed
NCT ID NCT06764160
Summary
This study tested the drug eculizumab in 15 Chinese patients with a severe, treatment-resistant form of myasthenia gravis, a disease that causes debilitating muscle weakness. The goal was to see if the drug was safe and effective at improving patients' ability to perform daily activities over 26 weeks of treatment. This was a Phase 3 study, meaning it was a later-stage trial to confirm the drug's effects in a specific population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Changchun, 130021, China
-
Research Site
Fuzhou, 350001, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Guangzhou, 510620, China
-
Research Site
Qingdao, 266035, China
-
Research Site
Shanghai, 200040, China
Conditions
Explore the condition pages connected to this study.